Press release
Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight
Lassa Fever Clinical Trials
Lassa Fever, an acute viral hemorrhagic disease endemic to West Africa, remains a serious public health challenge due to recurrent outbreaks and limited treatment options. Despite high fatality rates in severe cases, management is still mainly supportive, highlighting the urgent demand for effective antivirals and preventive vaccines.
By 2025, the Lassa fever pipeline includes over 3 active candidates, such as direct-acting antivirals, monoclonal antibodies, and next-generation vaccines. Leading players like Arisan Therapeutics and Imunon are advancing programs supported by international collaborations and expedited regulatory frameworks.
With increased focus on global pandemic preparedness, the Lassa fever pipeline is well-positioned to transform outbreak response, bringing scalable and sustainable solutions to endemic regions and beyond.
Interested in learning more about the current treatment landscape and the key drivers shaping the Lassa Fever pipeline? Click here: https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Lassa Fever Pipeline Report
• DelveInsight's pipeline review highlights 3+ active companies developing 3+ pipeline drugs for Lassa Fever.
• Leading companies such as Arisan Therapeutics and Imunon are advancing assets aimed at improving Lassa Fever management.
• Prominent candidates include ARN-75039, IMNN-102, and others.
• March 2025: Institut Pasteur, Paris, launched a Phase Ia trial of MOPEVAC-Lassa, a viral vector vaccine, enrolling 72 volunteers with dosing planned for 2026.
• March 2025: The US NIH/NIAID initiated a Phase I trial for LASSARAB, a rabies-vectored vaccine, enrolling up to 55 adults at the University of Maryland.
• January 2025: The West Africa Lassa Fever Consortium (WALC) introduced a multi-country Phase II/III adaptive trial framework to evaluate multiple therapies in endemic regions.
• August 2024: IAVI began a multisite Phase II trial in Ghana, Liberia, and Nigeria for its Lassa vaccine, enrolling 612 participants (adults, adolescents, and children).
Request a sample and discover the recent breakthroughs happening in the Lassa Fever pipeline landscape at https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Lassa Fever Overview
Lassa fever is a viral hemorrhagic illness caused by the Lassa virus of the Arenaviridae family. Endemic in West Africa (notably Nigeria, Sierra Leone, Liberia, and Guinea), it is spread mainly through contact with food or household items contaminated by infected Mastomys rats. Human-to-human transmission also occurs, especially in healthcare settings lacking infection control.
While most infections are mild or asymptomatic, severe cases can lead to multi-organ failure, hemorrhage, neurological issues, respiratory distress, and death. The incubation period is 6-21 days, with symptoms often mimicking other febrile diseases like malaria, complicating diagnosis.
There is currently no approved vaccine. Treatment is mainly supportive, though ribavirin has shown some benefit when given early. Due to its severity, outbreak potential, and risk to healthcare workers, Lassa fever is designated by the WHO as a priority pathogen, spurring global efforts to develop vaccines, monoclonal antibodies, and antivirals.
Find out more about Lassa Fever medication at https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Lassa Fever Treatment Analysis: Drug Profile
ARN-75039 (Arisan Therapeutics)
ARN-75039 is a broad-spectrum entry inhibitor targeting arenaviruses. Preclinical studies in guinea pigs demonstrated strong antiviral activity with oral dosing (60 mg/kg for 14 days), reducing severity and improving survival. Currently in Phase I clinical trials, ARN-75039 represents a key step toward advancing therapies for Lassa Fever and related viral hemorrhagic infections.
Learn more about the novel and emerging Lassa Fever pipeline therapies at https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Lassa Fever Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Pre-clinical and Discovery candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies
Dive deep into rich insights for drugs used for Lassa Fever treatment, visit: https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Lassa Fever Pipeline Report
• Coverage: Global
• Key Companies: Arisan Therapeutics, Imunon, and others
• Key Pipeline Therapies: ARN-75039, IMNN-102, and others
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight here
News-ID: 4150755 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Lassa
Lassa Fever Market Insights Highlight Expanding Outlook Till 2034, DelveInsight …
The Lassa Fever market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lassa Fever pipeline products will significantly revolutionize the Lassa Fever market dynamics.
DelveInsight's "Lassa Fever Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lassa Fever, historical and forecasted epidemiology as well as the Lassa Fever market trends in the United…
Lassa fever market is expected to reach USD 210 million by 2034
Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus, an arenavirus endemic to West Africa. It spreads primarily through contact with food or household items contaminated by rodents (Mastomys natalensis) or through person-to-person transmission in healthcare settings. With an estimated 100,000-300,000 infections annually and ~5,000 deaths, Lassa fever poses a serious public health threat.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71747
Currently, there is no approved…
Lassa Fever Treatment Market, Unraveling Innovations and Strategic Solutions for …
Overview of the Lassa Fever Treatment Market
The global Lassa fever treatment market has been rapidly gaining traction as the prevalence of this viral disease continues to impact public health worldwide. Lassa fever is an acute viral hemorrhagic disease caused by the Lassa virus, primarily transmitted by rodents, particularly the Mastomys species, which are found in parts of West Africa. While Lassa fever has a relatively low mortality rate compared to…
Lassa Fever Market Size, Analysis, Industry Statistics and Latest Insights Till …
Market Overview:
The lassa fever market is expected to exhibit a CAGR of 3.84% during 2023-2033. The lassa fever market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the…
Lassa Fever Treatment Market Trends, Growth Development, Key Opportunity, Applic …
When building an excellent Lassa Fever Treatment Market report, myriad of objectives of the marketing research have been kept in mind. All the data and statistics included in this report is derived from the reliable sources only e.g. journals or white papers of companies etc. This market research report contains several parameters which are thoroughly studied by the experts. This market analysis report provides with a thorough analysis of market…
Lassa Fever Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Lassa Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lassa Fever Market , historical and forecasted epidemiology as well as the Lassa Fever Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Lassa Fever Market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lassa Fever…
